News
इंस्टीट्यूट ऑफ गुड मैन्यूफैक्चरिंग प्रैक्टिसेज इंडिया
Institute of Good Manufacturing Practices India

(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)

ADMISSIONS NOTICE
18001031071 (Toll Free), +91 11 26512850
Regular Classroom | Online Mode
A new report states an increase in nurses? burnout risk due to Dissatisfaction with Electronic Health Records.
New map shows around 36 facilities in Texas identified as possible micro plastic polluters due to accumulation of ?nurdles?.
American Cancer Society, Color Health to facilitate free at-home colorectal cancer screening in underserved rural communities
Roche responds to WHO?s declaration of a global health emergency because of the ongoing mpox outbreak
US FDA approves the next-generation, AI-powered platform for Aquablation therapy-PROCEPT BioRobotics? HYDROS Robotic System
US FDA clears Insulet SmartAdjust technology, a device to power automated insulin dosing for individuals with type 2 diabetes
WHO introduces global strategic preparedness and response plan to stop outbreaks of human-to-human transmission of mpox
Fischer Medical partnership with Tech Avant-Garde to empower health programmes in Indian educational institutions
Qure.ai introduces FDA-cleared AI solution for advanced lung nodule quantification on CT scans at AABIP (American Association for Bronchology and Interventional Pulmonology) 2024
Bayer reports positive data from phase III FINEARTS-HF study of finerenone in patients with heart failure and LVEF at ESC Congress 2024
HERCULES phase 3 study of tolebrutinib to treat non-relapsing secondary progressive MS meets key primary endpoint : Sanofi
Emergency Use Authorization to Novavax 2024-2025 Formula Covid-19 vaccine to prevent Covid-19 in individuals aged 12 and older: US FDA
VitusCare motivates female patients to undergo regular dialysis on the occasion of Women?s Equality Day
Qiagen expands collaboration with AstraZeneca to develop and commercialize companion diagnostics, QIAstat-Dx
European Commission authorises expanded age indication for GSK?s Arexvy: The first respiratory syncytial virus vaccine for adults aged 50-59 at increased risk